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ABSTRACT: 
Background: 
The tumor progression and metastasis in breast cancer are 
angiogenesis dependant. Elastosis, the presence of clumps of elastic 
fibers, is known to occur frequently in association with breast carcinoma. 
Aim: To grade angiogenesis and elastosis in Fibrocystic breast disease 
and Invasive duct  breast carcinoma and correlate them with grade . 
Material and Methods: 
          30 cases of fibrocystic breast disease and 30 cases of invasive 
breast carcinoma were selected and immunohistochemistry with CD34 
markers and special stain with verhoff von gieson stain was done for all 
cases. 
Results: 
         The severe grade of microvessel density is prognostically 
significant in Fibrocystic disease with epithelial hyperplasia and Invasive 
duct  breast carcinoma - Nos  type cases with high grade (gradeIII) 
histological tumors. The significance of grade of elastosis  in Fibrocystic 
breast disease and Invasive  ductal breast carcinoma is obscure. 
 
 
 
 
Conclusions: 
       The microvessel density may have a role as one of the prognostic 
factors in node negative ductal breast carcinomas. 
Keywords: 
Fibrocystic breast disease, Invasive duct breast carcinoma – Nos type  
Angiogenesis , Microvessel density grade, ,Elastosis grade. 
 
1 
INTRODUCTION 
 
 Fibrocystic disease is one of the most common benign condition 
of the breast. Its incidence is significantly increased by nulliparity, late 
age of first birth, and late menopause
26
, factors also associated with 
increased risk for breast carcinoma risk. The diet such as high intake of 
meat fat and caffeine
2
 have  been associated with a greater risk of 
proliferative breast disease. Ductal and lobular hyperplasia, cyst 
formation, adenosis and fibrosis are major morphologic changes of 
Fibrocystic breast  disease.  
 
Ductal hyperplasia is a frequent constituent of fibrocystic change 
that may be detected by mammography or as a palpable tumor. 
Moderate or florid hyperplasia without atypia and sclerosing adenosis 
both are at slightly increased risk of breast carcinoma.
2,4 
 
Breast cancer is the second most common cancer in women.In  
2007 an estimated 178,480 women were diagnosed with invasive breast 
cancer
12
, 62,030 with carcinoma in situ, and over 40,000 women died of 
the disease. Breast cancer is the second leading cause of cancer related 
deaths in females all over the world. It has doubled in India in the last 
2 
two decades. As per study conducted in Coimbatore, percentage of 
occurrence of breast cancer was found to 10.5% (159 cases /year). 
 
The angiogenesis associated with breast carcinomas has attracted 
interest as a prognostic indicator
4
. Pathologic studies of angiogenesis in 
breast carcinoma have examined the relevance of tumor vascularity to 
known prognostic markers and to prognosis. To perform such studies 
histologic sections of paraffin embedded tissue are stained with 
immunohistochemical markers for endothelial cells such as CD34. In 
this study  the objective is to assess the role of angiogenesis on disease 
progression from FCD to  breast carcinoma. 
 
High microvessel density has been shown in some studies to be 
associated with a poor grade of histologic differentiation in invasive 
duct carcinomas and with a greater probability of axillary nodal 
metastases
27
. 
 
Epithelial hyperplasia is a premalignant component of fibrocystic 
breast disease and shows higher degree of elastosis
114
  when compared 
to other morphologic changes of FCD. The significance and 
pathogenesis of elastosis in breast carcinoma is unknown. It is common 
in infiltrating ductal and lobular carcinomas of the breast. 
3 
AIM OF STUDY 
 
         To assess microvessel density and elastosis in fibrocystic breast 
disease and invasive breast carcinoma. 
4 
OBJECTIVES 
 
1) To grade microvessel density using CD34 immunohistochemical 
marker in fibrocystic breast disease and invasive duct carcinoma. 
2) To grade of elastosis using Verhoffs VanGieson stain in fibrocystic 
breast disease and invasive duct carcinoma. 
3) To correlate grade of elastosis  and score (grade) of microvessel 
density with ductal epithelial hyperplasia in  fibrocystic breast 
disease. 
4) To correlate grade of elastosis and score (grade) of microvessel 
density with histological grade of invasive duct carcinoma. 
 
                        
5 
REVIEW OF LITERATURE 
 
 Fibrocystic disease is one of the most common benign condition 
of the breast. Its incidence is significantly increased by nulliparity, late 
age of first birth, and late menopause, factors also associated with 
increased risk for breast carcinoma
27
 . The diet such as high intake of 
meat fat
2
 and caffeine have been associated with a greater risk of 
proliferative breast disease. 
 
The ductal and lobular hyperplasia, cyst formation, adenosis and 
fibrosis are major morphologic changes of FCD. The ductal hyperplasia  
is a frequent constituent of  fibrocystic changes that may be detected by 
mammography or as a palpable tumor. Moderate or florid hyperplasia 
without atypia and sclerosing adenosis both are at slightly increased risk 
of breast carcinoma. 
 
Breast cancer is the most common site specific cancer in women 
and is the leading cause of death  for women aged 20 to 59 years.  High 
incidence in North America and northern Europe (91.4 new cases per 
100 000 women/year), intermediate incidence in southern European and 
Latin American countries, and low incidence in Asian and African 
countries
12
.
 
6 
In the United States, there has been a sharp increase in the 
detection of breast carcinoma, largely due to the widespread use of 
mammography
20
. Most of these cases have been localized, measuring 
less than 2 cm in diameter with/without situ carcinoma. The breast 
cancer mortality rate has (or) ocmedown from 30%to20% because of 
early screening and more effective treatment. 
 
ANATOMY OF BREAST  
 
The Breast (Mammary gland) is a highly modified apocrine sweat 
gland, made up of lobules and ducts. The mammary gland is covered 
with skin and subcutaneous tissue and rests on pectoralis muscle, from 
which lobules it is separated by a fascia.
2
  
 
The functional unit of breast is composed of two major parts: 
Terminal duct lobular unit (TDLU) and larger duct system. The TDLU
2
 
is formed by the lobule and terminal ductule and represents the 
secretory portion of the duct. 
 
7 
TERMINAL DUCTAL LOBULAR UNIT 
 
 
 
 
 
 
 
 
 
 
 
 
The functional unit of breast is composed of two major parts:  
(1) Terminal duct lobular unit (TDLU)  
(2) Larger duct system.  
 
The TDLU is formed by the lobule and terminal ductule and 
represents the secretory portion of the duct. 
8 
BREAST ANATOMY 
 
9 
HISTOLOGY OF BREAST: 
 
The lobules are separated by less dense collagenous interlobular 
tissue, whereas the intralobular supporting tissue surrounding the ducts 
within each lobule is less collagenous and more vascular.  
The ducts and lobules are lined by inner secretory epithelial cells 
and outer myoepithelial cells
1
. Epithelial cells are columnar or cuboidal 
cells, and myoepithelial cells situated under epithelial cells have  
smaller, dark nuclei  
 
H & E Section Shows Terminal ductal lobular unit  
10 
FIBROCYSTIC DISEASE OF BREAST: 
 
Fibrocystic breast disease or change is a most common benign 
lesion of the breast consisting of cystic dilation of intra lobular glands. 
It occurs between the ages of 25 and 45 years. More than 50 % of 
women present with illdefined palpable mass, cyclical pain, and 
tenderness. The exact cause of FCD is not known, but hormones may 
have role in its development. 
 
Morphologic changes of FCD
2 
1. Cyst formation  
2. Apocrine metaplasia  
3. Fibrosis  
4. Adenosis   
5. Calcification  
6. Chronic inflammation  
7. Epithelial hyperplasia                  
8. Fibroadenomatoid change. 
 
11 
1. CYSTS:  
 Grossly multiple cysts are seen and measure between 2mm to 
lessthan 1 cm in size. Microscopically cysts are lined by a flattened 
atrophic epithelium or by metaplastic apocrine cells
2
. 
 
2. FIBROSIS: 
 It is secondary to rupture of the cysts
2
. 
 
3. APOCRINE METAPLASIA: 
 Apocrine metaplasia
2 
is a very common finding in fibrocystic 
disease. It is mostly seen in dilated and cystic structures. The apocrine 
cells have  abundant eosinophilic ,granular cytoplasm and round 
vesicular nuclei.      
     
4. ADENOSIS :   
 Adenosis refers to increase in the number of acini per lobule
12
.  
The acini are enlarged but not distorted. The acini are lined by benign 
appearing columnar cells. This lesion is the earliest recognizable 
precursor of epithelial neoplasia. Sclerosing adenosis is associated with 
moderately increased risk for breast carcinoma. 
 
 
12 
OTHER CHANGES : 
5. CALCIFICATION:  
 It is a less common change. Its chemical composition
2
 is calcium 
oxalate, easily identified on mammography and H&E sections. 
 
6. CHRONIC INFLAMMATION: 
 This results from rupture of cysts
2
. The inflammatory cells are 
lymphocytes, histiocytes and plasma cells. 
 
7. EPITHELIAL HYPERPLASIA: 
 It is the most significant
2
 pathology of FCD. The epithelial 
hyperplasia is defined by the presence of more than two cell layers. 
Microscopically the benign conditions of epithelial hyperplasia is 
identified by following features, 
 
1)  Nuclei are oval, normochromatic and with mild overlap; small, 
single, indistinct nucleoli; mild or no mitotic figures. 
 
2)  The cytoplasm is acidophilic and finely granular 
2
and the borders 
are indistinct. 
 
13 
3)  Streaming effect, induced by the oval cells being vaguely 
arranged in parallel bundles  and „Tufts‟ and „mounds‟ projecting 
into the lumen. 
 
4)  Presence of peripheral elongated clefts, bound on one side by a 
single layer of basally located cells and on the other by a solid 
intraluminal formation.  
 
  5)   Presence of irregularly shaped bridges connecting opposite 
portions of the wall. The cells in these bridges have oval nuclei 
arranged parallel to the long axis of the bridge. This is referred as 
Roman bridges.  
 
6)   Complete or incomplete apocrine metaplasia with cytoplasmic 
blebbing. 
 
7)   Presence of myoepithelial cells. 
 
8)  Presence of foamy macrophages, both in the lumen and 
intimately admixed with the proliferating epithelial cells. 
 
 9)    Stromal Calcification or intraluminal calcification are common. 
 
10)  Absence of necrosis. 
14 
8. FIBROADENOMATOID CHANGE: 
 It is rare change of FCD.A study conducted in 1998 by the 
Cancer Committee of the College of American Pathologists
27
defined the 
relative risk for breast carcinoma associated with proliferative breast 
lesions as follows. 
 
NO INCREASED RISK 
 Adenosis, other than sclerosing adenosis 
 Duct ectasia 
 Fibroadenoma lacking complex features 
 Fibrosis 
 Mastitis 
 Hyperplasia without atypia 
 Cysts, gross or microscopic 
 Simple apocrine metaplasia without associated adenosis 
 Squamous metaplasia  
 
SLIGHTLY INCREASED RISK  
 Complex fibroadenoma 
 Moderate or florid hyperplasia without atypia 
 Sclerosing adenosis 
 Solitary papilloma without atypical hyperplasia  
15 
MODERATELY INCREASED RISK  
 Atypical ductal hyperplasia. 
 Atypical lobular hyperplasia 
 
Sl.No. BREAST LESIONS 
RELATIVE RISK OF 
CARCINOMA 
1 Non proliferative breast lesion 3% 
2 
Proliferative breast disease without 
atypia 
5-7% 
3 
Proliferative breast disease with 
atypia 
13-17% 
4 Carcinoma in situ 25-30% 
16 
BREAST CARCINOMA: 
 Breast cancer is the most common site specific cancer in 
13
women and is the leading cause of death for women aged 20 to 59 
years. High incidence in North America and northern Europe (91.4 new 
cases per 100 000 women/year), intermediate incidence in southern 
European and Latin American countries, and low incidence in Asian 
and African countries
2
. 
 
 In the United States, there has been a sharp increase in the 
detection of breast carcinoma, largely due to the widespread use of 
mammography
13
. Most of these cases have been localized, measuring 
less than 2 cm in diameter with or without in situ carcinoma. The breast 
cancer mortality rate has slowly decreased from 30%to20% because of 
early screening more effective treatment. 
 
CLINICAL FEATURES OF BREAST DISEASE: 
1) Pain 
2) Palpable mass 
3) Lumpness 
4) Nipple discharge 
17 
RISK FACTORS OF BREAST CANCERS: 
1) AGE : 
 The peak incidence  at age of 75 to 80years and  rarely occurs in 
less than 25 years of age. Younger women with breast carcinoma have a 
worst prognosis than older women
66
. 
 
 2) AGE AT MENARCHE:  
  The risk of breast cancer is 20% increased with Women attained 
menarche at less than 11 years of age.  Late menopause also increases 
the risk of cancer
12
. 
 
3) RACE /ETHNICITY:  
 The risk of breast cancer is highest  in Non –hispanic white 
women. The P53 mutation are more common in African American 
women but less common in Hispanic women
12
.   
 
 4) AGE AT FIRST LIVE BIRTH: 
 The risk of breast cancer is higher in Women with first full-term 
pregnancy
12
 at ages less than 20 years and in women over the age of 35 
at their first birth or nulliparouswomen.  
 
 
18 
5)  PREGNANCY: 
 At the time of pregnancy
69
 the changes in stroma that leads to the 
growth and expansion of lobules facilitate the transition from in situ to 
invasive carcinoma.  
 
6) FAMILY HISTORY: 
 The risk is increased in first degree relatives. Only 13% of 
women with breast cancer have one affected first-degree relative, and 
only 1% have two or more. The family risk is due to low-risk 
susceptibility genes and nongenetic factors. The BRCA1 and BRCA2 
mutations
2,16,70 
are associated with increased risk of breast cancer. 
 
7) HORMONAL FACTORS: 
 The women taking postmenopausal hormone replacement therapy  
risk of breast cancer is increased in 1.2 to 1.7 fold. Most of the cancers 
are ER-positive carcinomas and invasive lobular carcinomas.  
Oophorectomy may decreasing endogenous estrogens which also 
reduce the risk of developing breast cancer by up to 75%. Low 
frequency of fibrocystic disease among long term use of oral 
contrceptives
29
. 
 
 
19 
8) ATYPICAL HYPERPLASIA AND FCD : 
 Atypical hyperplasia is associated with increased  risk of invasive 
carcinoma
2
. In FCD (Epithelial hyperplasia without atypia) is associated 
with moderate risk of breast cancer
2,4
. 
 
9) EXPOSURE OF RADIATION: 
 The radiation especially chest radiation
12
 is associated with high 
risk of developing breast cancer. 
 
10) CONTRALATERAL BREAST CANCER: 
 The possibilities that a patient with invasive breast cancer will 
acquire cancer in the contralateral breast 
18
 is about 5 times that of the 
general population and also higher in family history of breast 
carcinoma. The risk increased as 25%-50% in lobular carcinoma. 
 
11) DIET: 
 The risk is reduced with consumption of Caffeine and heavy 
consumption of alcohol
12
 is associated with increased risk of breast 
cancer. 
 
12) OBESITY: 
 The risk of breast cacer is decreased in premenopausal obese 
women, but  the risk high in postmenopausal obese women
12
 . 
20 
13) BREAST FEEDING: 
 The risk is decreased in breast feeding women. 
 
14) TUMOR LOCATION: 
 About 50% of the breast carcinoma is located in upper outer 
quadrant of breast then 15% in the upper inner quadrant,17%in the 
central region 10% in the lower outer quadrant and 5% in the lower 
inner quadrant
2
. 
 
15) TOBACCO: 
 The breast cancer not associated with smoking but that leads to  
periductal mastitis
12
. 
 
16) ENVIRONMENTAL TOXINS: 
          Organochloride pesticide is associated with increased risk of 
breast carcinoma.
12 
 
ETIOLOGY AND PATHOGENESIS: 
 The Genetic
16
 and Hormonal factors
30
 are the main risk factors 
for the growth of breast carcinoma. The breast cancer is divided in to 
sporadic breast cancer and hereditary breast cancer. 
21 
 The hereditary gene is a primary source of the breast carcinoma. 
The possibility of a hereditary etiology increases with variable affected 
1st-degree relatives.  
 
 The BRCA1 and BRCA2 mutation related  greater part  of breast 
cancers, attributable to single mutations and about 3% of all breast 
cancers. 
 
 
            Mutations in BRCA1 also manifestly raise the risk of rising 
ovarian cancer but mutation in BRCA2 confers a less risk for ovarian 
cancer and linked more commonly with male breast carcinoma.
12
  
 
 Mutation in BRCA1-related breast carcinomas are usually poorly 
differentiated  tumor and do not express hormone receptors (Triple 
negative cancer). The BRCA1 carcinomas are often linked with loss of 
the inactive X chromosome, resulting in the lack of the Barr body. 
 
MOLECULAR GENETICS OF BREAST CANCER: 
1. Growth receptor overexpression 
2. Growth factor overexpression 
3. Intracellular signaling molecule alterations 
4. Cellcycle regulator alterations 
 
22 
5. Adhesion molecule alterations 
6. CMYC amplification 
 
MOLECULAR SUSTYPES: 
1. 1.Luminal type (type A , B and C) 
2. HER2/neu type 
3. Normal breast –like 
 
Luminal A type   -50% of invasive breast carcinoma,  ER/PR positive 
and HER2/neu negative. Good prognosis
2
. 
 
Luminal B type-    20% of invasive breast carcinoma, ER/PR positive 
and variable expression of HER2/neu receptor. Respond to endocrine 
treatment and less prognosis. 
 
HER2/neu -  15% of invasive breast carcinoma,ER/PR negative and 
HER2/neu positive and respond to trastuzumab with poor prognosis. 
 
Basal –like   -  15% of invasive breast carcinoma. Majority of ER/PR  
and HER2/neu receptors are negative and   no respond to trastuzumab  
or endocrine treatment with poor prognosis
2
. Basal-like types is 
extremely heterogenous, and encompasses a few tumors  with good 
23 
prognosis, such as secretory carcinoma, medullary carcinoma  and 
adenoid cystic carcinoma. 
 
 
 SPORADIC BREAST CARCINOMA : 
 The main risk factors for sporadic cancer
12
are associated with 
hormone introduction, sex, age at menarche and menopause, 
reproductive record, breast feeding, and exogenous estrogens. The 
majorities of sporadic carcinoma arise in postmenopausal women and 
are positive estrogen receptors. 
 
INVESTIGATIONS: 
 
1) CLINICAL EXAMINATIONS: 
 It is age old method for the detection and evaluation of breast 
disease. It als most useful method
2
 for physician and patient herself.  
The clinical impressions are incorrect in 15% of benign cases and 10% 
of cases of malignant.   
  
 Axillary lymph node examination is also important. The positive 
nodes will be found free of metastases microscopically in 15% of 
cases. 
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2) MAMMOGRAPHY:  
 
 The widespread use of mammography
20
 has a important 
diagnostic method of breast cancer. The small tumors (1–2 mm) can be 
identified by mammography. It usually appears on mammography on 
the presence of calcification. The incidence of calcification associated 
with breast carcinoma is about 50-60%
2,4
. 
 
              The negative mammogram does not rule out the possibility of 
the presence of carcinoma, since about twenty percent of palpable 
tumors are not detectable with this technique and false positive 
incidence is 1%.  
 
           The proper handling of breast lesions detected by mammography 
requires team work of radiologist, surgeon, and pathologist. The 
Abnormal area identified on mammography, provides the surgeon with 
a doubtful  area within the breast.  
 
After excision of specimen lateral margins should be marked by 
sutures and an x-ray study taken of the specimen. If no lesion is seen, 
the surgeon should obtain additional tissue.  
 
 
 
25 
3) MRI IMAGING: 
 The nuclear magnetic resonance with contrast-enhanced 
techniques are more informative and most useful method of breast 
carcinoma. It is also more sensitive for the detection of multicentric 
breast cancer. 
 
4) ULTRASONOGRAPHY: 
 It is particularly for detection of cystic or solid lesions. 
 
5) CYTOLOGY: 
 The two methods are used to obtain cytologic material from 
breast lesions are 
(1)  Aspiration of nipple secretion  
(2)   Fine needle aspiration cytology (FNAC).  
 
 The cytology of nipple secretion is now limited useful method for 
breast lesions. FNAC
21
 is indicated in all palpable breast lesions. It is a 
rapid, accurate and cost effective method of diagnosis. The sensitivity is 
about  87%, the specificity is about 100%
2,13
. The adequacy of breast 
FNAC is about six clusters of epithelial cells spread over two glass 
slides. 
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  The most of benign lesions of breast misdiagnosed cytologically 
as  malignant lesions such as  the fibrocystic breast disease  with 
marked epithelial proliferation
2,4
. On cytologically distinguish between 
in situ and invasive ductal carcinoma is not possible. The histologic 
sections prepared from cell blocks of aspirated materials may help in 
identification of invasion. 
 
The role of FNAC  
1) To diagnosis of simple cyst 
1) The preoperative  confirmation of  clinically suspected cancer 
2) To investigate of suspected recurrence or metastasis in case of 
previously diagnosed cancer. 
3) To obtain tumor cells for special analysis such as IHC and DNA 
analysis. 
 
6) BIOPSY: 
 The needle core biopsy
2,22
 is a nonoperative diagnosis of breast 
cancer. This is based on the both cytologic and architectural features, 
and gives a correct diagnosis of invasive breast carcinoma and a benign 
breast lesions. It also helps to identify  microcalcifications. 
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 In addition, prognostic indicators (ER, PR, HER2/neu, etc.) can 
be evaluated in core needle biopsies. Accurate diagnosis of a core 
biopsy is about >90% . 
 
A) OPEN BIOPSY: 
It is two types 
1) Excisional biopsy     
2) Incisional biopsy 
 
 The excisional biopsy usually performed in when the tumor 
measures 2.5 cm or less and the incisional biopsy for larger tumors. 
This technique is highly accurate and the false positive rate is 0 %, the 
false negative rate is<1 %. 
 
B) FROZEN SECTION: 
 It is most useful method for the confirmation of a cytologic 
diagnosis breast  carcinoma or the evaluation of surgical margins
2,23
.  
 Disadvantages: Difficulties with frozen sections are usually 
attributable to  
(1) Sampling errors 
(2) Technical errors  
(3) Histologic misinterpretation.  
28 
 The intraoperative cytologic examination can be taken 
simultaneously with the frozen section procedure. 
 
7) SENTINAL NODE BIOPSY: 
 
 It is based on the sentinel node
58,59
 is negative, the other nodes  
also be negative. But the sentinel node is positive the changes of other 
nodal metastasis is about one third cases.  
 
The tumor size and the presence of lymphovascular invasion  
most predictors of positive sentinel nodes. A focal metastasis in a 
sentinel node is mostly located in the region of the inflow junction of 
the afferent lymph vessel than other sites. 
 
8) ANCILLARY STUDIES: 
 To assess the estrogen and progesterone receptor status is a 
important prognostic indicater and also used to the treatment choice in 
patients with breast cancer.  
 
 The ER and PR receptors
2,4
 are measured  by immuno 
histochemical method. The majority of breast carcinomas are ER 
positive(80%). 
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SPREAD AND METASTASES: 
The breast cancer spread by 
1. Direct invasion  
2. Lymphatic spread  
3. Blood vessel route.                     
4. Local invasion  
5. The distant metastasis to other organs. 
 
 The stromal invasion 
2,9
can be by direct extension or 
intramammary lymph vessels, and also by the tissue spaces are known 
as „pseudoangiomatous stromal hyperplasia‟. Local recurrence after 
mastectomy appears as superficial nodules.  
 
The most common sites for distant metastasis of breast cancer is 
lung, pleura, liver, ovary, adrenal gland and central nervous system. 
Invasive lobular carcinoma is associated with metastasis to the 
gastrointestinal tract, ovaries and serosal surfaces
2,4
. 
 
 The lymph node of axillary group and internal mammary lymph 
nodes are usually involved with metastatic breast carcinoma. \ 
 
 The supraclavicular lymph node involvement is less commonly 
involved
2;11
. The incidence of metastatic involvement of the breast 
carcinoma is approximately 22%. 
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TREATMENT: 
 The treatment of breast carcinoma is depends on the type and 
extent of the tumor. 
1) Surgery  
2) Radiation therapy 
 3) Hormonal therapy                              
 4) Chemotherapy  
5) Target therapy 
 
 The surgical therapy are Halsted's radical mastectomy, which 
include partial mastectomy and total (simple) mastectomy
6
. 
 
        Radiation therapy is employed in a postoperative adjunct and for 
the control of local recurrence of disease.  
 
 The chemotherapy 
2,4
is used as an adjunct therapy after local 
treatment and also used in patients with positive axillary nodes. 
 
         Chemotherapy has also been used in combination with 
conservative surgery and radiation in patients with localized large (>3 
cm) tumors in order to avoid mastectomy.  
         
 The hormonal therapy is used in all stages of estrogen receptor-
positive breast cancer
2,4 
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WHO CLASSIFICATION
73
 OF BREAST TUMORS: 
 
A) EPITHELIAL TUMORS: 
 
Invasive duct carcinoma, Not otherwise specified 
Invasive Lobular carcinoma 
Tubular carcinoma 
Invasive Cribriform carcinoma 
Invasive Papillary carcinoma  
Invasive Micropapillary carcinoma 
Medullary carcinoma 
Mucinous carcinoma 
Apocrine carcinoma 
Metaplastic carcinoma 
Secretory carcinoma 
Neuro Endocrine carcinoma 
Oncocytic carcinoma 
Adenoid cystic carcinoma 
Acinic cell carcinoma 
Glycogen rich clear cell carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
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Micro invasive carcinoma 
Intraductal proliferative lesions 
- Usual ductal hyperplasia 
- Flat ductal hyperplasia 
- Atypical ductal hyperplasia 
- Ductal carcinoma in situ 
         Intraductal papillary neoplasm 
-Central papilloma  
-peripheral papilloma 
-Intraductal papillary carcinoma 
Benign epithelial proliferation 
                -Adenosis  and its variant 
                 -Radial scar or complex sclerosing lesion 
                  -Adenomas and its variants 
 
B) MYOEPITHELIAL LESIONS: 
 
             - Myoepitheliosis 
             - Adenomyoepithelial adenosis 
             - Adenomyoepithelioma 
            - Malignant myoepithelioma 
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B) MESENCHYMAL TUMORS: 
 
             - Hemangioma  
            -Angiomatosis 
            - Hemangiopericytoma 
            - Myofibroblastoma 
             - Fibromatosis 
           - Inflammatory  myofibroblastoma 
          - Lipoma, Leomyoma 
          - Granular cell tumor 
          - Neurofibroma 
         - Schwannoma 
          - Angiosarcoma, Liposarcoma, Rhabdomyosarcoma, 
            Osteosarcoma  And Leomyosarcoma 
 
D) FIBROEPITHELIAL TUMORS: 
          - Fibroadenoma 
           - Phylloides tumor 
           - Periductal stromal sarcoma 
           - Mammary hamartoma 
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E) TUMORS OF NIPPLE: 
             - Nipple adenoma 
             - Paget disease of nipple 
 
F) MALIGNANT LYMPHOMA: 
            - Diffuse Large B cell Lymphoma 
             - Burkitts Lymphoma 
             - Extra nodal marginal zone B cell Lymphoma of MALT type 
             - Follicular Lymphoma 
 
G) METASTATIC TUMORS 
 
H) TUMORS OF MALE BREAST: 
 - Gynaecomastia 
-Carcinoma- nvasive and insitu 
 
DUCTAL CARCINOMA IN SITU (DCIS): 
       DCIS is also refered as intraductal carcinoma
2
 of the breast. It 
consists of a malignant clonal population of cells limited to ducts and 
lobules by the basement membrane
94
. The myoepithelial cells are 
preserved. 
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Morphologic variants: 
1) Comedocarcinoma 
2) Solid variant  
3) Cribriform variant 
4) Papillary variant  
5) Micropapillary variant  
6) Clinging variant 
7) Cystic hypersecretory variant. 
 
COMEDOCARCINOMA
94
: 
         Grossly it shows a cluster of thick walled ducts with normal 
breast parenchyma. The evidence of necrosis is present.  
 
         Microscopically  tumor cells are arranged in solid sheets. The 
tumor cells exhibit high degree of hyperchromasia and 
pleomorphism.Necrosis and mitosis is present. The myoepithelial cells 
surrounds the duct. The stroma shows  periductal fibrosis, infiltration of 
mononuclear cells
2,9
. 
 
SOLID VARIANT: 
        The proliferating cells completely fill within the gllndular lumen. 
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CRIBRIFORM VARIANT: 
     In this lesion  intraepithelial spaces are evenly distributed and are 
regular in shape. 
 
PAPILLARY VARIANT: 
      The papillary variant arises fom large ducts. Grossly it a well 
defined  mass.Microscopically  the tumor cells are arranged in 
papillary
95
 paterrn with fibrovascular core.The tumor cells show,loss of 
nuclear polarity ,marked hyperplasia and lack of myoepithelial cells. 
 
DUCTAL INTRA EPITHELIAL NEOPLASIA(DIN): 
      1a-related to usual ductal  hyperplasia, 1b-related to flat epithelial 
atypia, 1c-related to ADH and small grade IDCIS,  2-related to large 
grade I DCIS and grade II DCIS, 3-related to grade III DCIS. 
 
CLASSIFICATION OF DCIS: 
A. Lagios  classified by 
                    -High grade DCIS 
                    -Intermediate grade DCIS 
                    -Low grade DCIS 
 
B. Nottingham classified by 
                   -Pure comedo DCIS 
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                    -DCIS with necrosis 
                      - DCIS without necrosis 
 
C. Van nuys classified by 
                    -High grade DCIS 
                    -Non high grade DCIS with necrosis 
                     -Non high grade DCIS without necrosis 
 
D. Holland and Hendricks classified 
                      -Poorly differentiated DCIS 
                      -Intermediately differentiated DCIS 
                         -Well differentiated DCIS 
 
E.  NHSBSP/EEC classified  
                         -High grade DCIS 
                         -Intermediate grade  and  low grade DCIS 
DCIS MICROSCOPIC FEATURES: 
1. Luminal bridges and intercellular spaces appear rigid. 
2. Presence of necrosis. 
3. Evenly distributed cells 
4. Monomorphic population of tumor cells 
5. Apocrine metaplastic foci are not seen 
6. Streaming of nuclei not seen 
38 
7.  Minimal nuclear pleomorphism and nuclear hyperchromasia 
,prominent nucleoli are present. The mitotic figures are 
inconsistent. 
 
PROGNOSTIC INDEX  OF DCIS:(VANNUYS PROGNOSTIC 
INDEX) 
 1. Lesion size  
                    Score1-  ≤ 15mm 
                   Score  - 16 - 40mm 
               Score 3 - > 40mm 
 
2. Margin 
   Score1-. >10mm 
 Score2 -1to 9mm 
 Score 3-  <1mm 
 
3. Histology 
   Score1-. Non high grade without necrosis 
 Score2 - Non high grade with necrosis 
               Score 3-  High grade 
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AJCC STAGING OF BREAST CARCINOMA 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 N1 M0 
  T1 N1 M0 
  T2 N0 M0 
Stage IIB T2 N1 M0 
  T3 N0 M0 
Stage IIIA T0 N2 M0 
  T1 N2 M0 
  T2 N2 M0 
  T3 N1 M0 
  T3 N2 M0 
Stage IIIB T4 N0 M0 
  T4 N1 M0 
  T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T AnyM  
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INVASIVE DUCTAL CARCINOMA NOS TYPE: 
 Invasive ductal carcinoma are malignant tumors of the breast 
which have the tendency to invade the adjacent normal breast tissues 
and also the distant organs
2,4
. They can be classified into various 
histological types. Invasive duct carcinoma not otherwise specified 
(NOS) is the most common type. Others names used are, Ductal 
carcinoma, Carcinoma not otherwise specified and invasive carcinoma 
of no special type.  According to WHO it  is called Invasive duct 
carcinoma ,no special type, and it  about 75-80% of breast carcinoma. 
 
 The chief presenting complaint in   carcinoma breast is palpable 
lump. The size of tumor is variable from 1 cm to several 
centimeters in diameter. Cut surfaces  are firm to hard and the 
margins are well or poorly defined. About 2 percent of the patients 
present with the synchronous bilateral tumors. Pain and nipple 
discharge is rare presenting complaint of breast carcinoma.  
 
        The mammographic evaluation of breast screening has changed 
the pattern of presentation .With the help of mammographic screening  
most of the patients with breast carcinomas  detect impalpable 
mammographic abnormality. 
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 The  mucinous (colloid ) carcinoma,   tubular carcinoma,  
papillary carcinomas, medullary carcinoma, secretory carcinoma, and 
adenoid cystic carcinoma are breast carcinomas with favourable 
prognosis. Where as metaplastic carcinoma, pleomorphic lobular 
carcinoma and inflammatory carcinoma have unfavourable prognosis. 
 
 As per the American Cancer Society
6
, about two-thirds of women 
with an invasive duct carcinoma NOS are 55years or older. The overall 
survival rate is 55-65%. 
 
HISTOLOGICAL SPECTRUM OF INVASIVE BREAST 
CANCER 
1) Invasive ductal carcinoma –NOS type  - 70-89% 
2) Invasive lobular carcinoma                    -      10% 
3) Tubular / Cribriform carcinoma              -     06% 
4) Medullary carcinoma                           -        02% 
5) Mucinous carcinoma                             - 02% 
6) Papillary carcinoma                               - 01% 
7) Metaplastic carcinoma                           -  < 01% 
8) Others                                                       - 13% 
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INVASIVE   DUCT CARCINOMA NOS TYPE: 
 
Histopathology: 
Gross :   
It is poorly circumscribed, firm to hard, gritty to cut, with chalky 
white streaks. The size may vary from 0.5-10cm. 
 
Microscopy :   
Tumor cells are arranged in diffuse sheets, well defined nest, or 
as individual cells. The nuclei are regular or large pleomorphic with 
prominent nucleoli. Depending on the grade of the tumor the mitotic 
figures are varible.  
 
 The stroma are densely fibrotic
2,4
 to highly cellular. Areas of focal 
necrosis, squamous metaplasia and apocrine metaplasia or clear cell 
changes are seen. Over 90% of cases associated with elastosis. In 
between tumor and sroma shows variable amounts of mononuclear 
inflammatory infiltration.  
 
According to study conducted by Fisher et al the percentage of 
perineurial, lymph vessel and blood vessels invasion are 28%,33% and 
5% of cases respectively. 
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OTHER SPECIAL TYPES: 
TUBULAR CARCINOMA: 
 
 The incidence of tubular carcinoma
34
 is 1-3 %.Tubular carcinoma 
is a well differentiated tumor and have an good  prognosis. 
 
Gross:  
Tubular carcinoma is usually small, and about 1 cm in diameter. 
Cut surface shows ill defined firm to hard greyish white tumor usually 
lessthan 2cm in size. 
 
Histopathology:  
Microscopically it is characterized by haphazardly arranged 
irregular angulated tubules witen lumen with basophilic secretion.The 
lumen lined by only one layer of epithelial cells with mild nuclear 
pleomorphism and rare mitosis. The stroma is abundant and cellular. 
Periphery of the lesion shows invasion of fat also seen. 
 
CRIBRIFORM CARCINOMA: 
 It‟s rare form of invasive carcinoma with an excellent 
prognosis
35
. The incidence is >3%. 
 
Gross: 
  solid greyish white in appearance. 
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Histopathology: 
  Tumor cells arranged in cribriform pattern. Tumor cells are 
small cells and exhibit mild or moderate degree of pleomorphism and 
rare mitosis. Stromal invasion may be present. 
 
MUCINOUS CARCINOMA: 
 The incidence of the tumor is 1-4%.It also known as colloid 
carcinoma
36
. These are tumors in which mucin production is apparent to 
naked eye. It usually occurs in postmenopausal women and has a 
favorable prognosis. 
 
Gross:  
 Well defined mass with a soft  and gelatinous consistency. Areas 
of hemorrhages are more common. 
 
Histopathology:  
Small clusters of regular epithelial cells floating in a pool of 
extracellular mucin .The tumor cells are small with darkly staining 
nuclei which exhibit mild pleomorphism. Mitoses are rare. 
 
MEDULLARY CARCINOMA: 
 The  frequency varies between 2-10 % and common in Japanese 
women and mostly associated  with BRCA1 mutations. 
45 
Gross:  
Well circumscribed large tumor with pushing margins and  soft  
consistency. 
 
Histopathology:  
Three main morphologic criteria for diagnosis of medullary 
carcinoma
2
,
37 
1. Tumor cells are arranged in  Syncytial pattern of growth. The 
malignant cell are pleomorphic nuclei  and nucleoli are 
prominent.   
2. The  stroma shows lymphoplasmacytic infiltration. 
 
INVASIVE PAPILLARY CARCINOMA: 
 It constitutes <1% of cases. It  usually occurs  in elderly. It is 
entirely insitu lesions
38
. 
 
Gross:  
 Most of the tumors are well demarcated  mass  measures 1to 3cm, 
and soft in consistency.
 
 
Histopathology :   
The malignant cells  are arranged in  papillary growth pattern. 
The nuclear atypia is mild to moderate. PapillaryCIS present in more 
than 70%  of cases.
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INVASIVE MICROPAPILLARY CARCINOMA: 
 Rare variant of infiltrative carcinoma with poor prognosis.
2,4,39
 
Gross: It is expansive growth and lobulated appearance. 
 
Histopathology:  
Cluster of tumor cells arranged in a micropapillary or tubular-
alveolar  pattern without a fibrovascular core . This tumor is usually 
associated with  high incidence of vascular invasion
40
 and lymph node 
involvement .Over 50% of cases associated with psammoma bodies. 
 
SECRETORY CARCINOMA : 
 It is rare tumors occurs  usually  in childhood, but also occur in 
adolescence .  
 
Gross:  
Well circumscribed  tumor mass, usually  small in size ( less than 
2 cm in diameter). 
 
Histopathology:  
It composed of three histologic  pattern
41
  
(1)  Microcystic pattern composed of small cysts. 
(2)  Compact solid pattern.  
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(3) Tubular pattern which contains numerous tubular spaces and 
containing secretions. Tumor cells have abundant pale eosinophilic 
cytoplasm with mild pleomorphic nuclei.  
 
 Tumor shows a well defined border with peripheral fibrosis. The 
diagnostic feature is the presence of intra and extracellular rounded 
vacuoles giving a overall clear cell pattern. The mitosis is infrequent. 
These vacuoles positive stain for Alcian blue and PAS with diastase 
resistant. 
 
APOCRINE CARCINOMA: 
Its rare type of invasive duct carcinoma
40
 with prominent 
apocrine differentiation. The incidence is 1 to 4%. 
 
Gross:  
Cut surface shows brownish –tan colour 
 
Histopathology:  
The tumor cells are arranged  cords, tubules and solid pattern
2,4
. 
The malignant cells are large cells have abuntant eosinophilic granular 
cytoplasm with vesicular hyperchromatic nuclei,and prominent 
nucleoli.Apocrine snout is seen in luminal portion of tumor. 
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METAPLASTIC CARCINOMA: 
 Metaplastic carcinoma
42
 rare malignant tumor with  admixture of 
(adeno)carcinoma and spindle cells, squamous cells,  chondroid or 
osseous changes also occur.  
 
Gross: 
 Large , nodular tumors usually greater  than 5cm in diameter 
and fixed to deep fascia. 
 
Histopathology: 
 Malignant epithelial elements show transtition to sarcomatous 
elements which includes  cartilage, bone, myxoid stroma and spindle 
cell stroma
2,4
.It is a highly malignant tumors with early recurrence 
and low survival rate. 
 
Types are 
(1) sarcomatoid carcinoma  
(2) Spindle cell carcinoma   
(3) Carcinoma with osteoclast –like giant cells  
(4) squamous cell carcinoma                           
(5) melanocytic differentiation, choriocarcinomatous type, and 
pleomorphic carcinoma.  
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CARCINOMA WITH NEUROENDOCRINE 
DIFFERENTIATION: 
 
It also known as Carcinoid tumor. Bilateral locations and 
multicenticity can  occur
43
. 
 
Gross:   Usually well circumscribed growth. 
 
Histopathology:  
Tumor is composed of epithelial and spindle cells. The tumor 
cells are small cells and arranged in solid nests ,separated by fibrous 
tissue.The tumor cells show a “salt-and-pepper” chromatin pattern and 
fine granular, eosinophilic cytoplasm. Intracytoplasmic mucin also seen. 
 
OTHER RARE TUMORS: 
 Squamous cell carcinoma, Clear cell carcinoma, Lipid rich 
carcinoma, Inflammatory carcinoma, Adenoid cystic carcinoma, Acinic 
cell carcinoma  and metastatic carcinoma. 
 
LOBULAR CARCINOMA :  
Gross:   
Firm to hard mass and tumor borders are irregular and  formation 
of many small hard nodules recembling  sclerosing adenosis
2,4
. 
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Histopathology: 
 Classic variant: Small uniform cells growing in a single file and 
in a concentric fashion around the lobules. The stroma is abundant and 
dense fibrous and containing foci of periductal and privenous 
elastosis
2,4
. The individual cells are small round to ovoid with little 
cytoplasm and eccentrically placed nucleus exhibiting mild 
pleomorphism and infrequent mitoses and Lymphocytic infiltration  
also present. 
 
 
Other variants include: 
Alveolar variant: 
Cells similar to classic type arranged in aggregates of 20 or more cells. 
 Solid variant:  
 Tumor cells arranged  in diffuse sheets   and  the stroma is 
scanty. 
 
Tubulolobular variant: 
 Cells arranged in tubules and cords . These tubules are small in 
amounts. 
Pleomorphic variant: 
 Classical lobular infiltrative pattern with cells exhibiting 
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cellular atypia and nuclear pleomorphism
45
. These cells have more 
eosinophilic cytoplasm. 
Histiocytoid carcinoma:
46 
 
Tumor arranged in diffuse growth pattern. The malignant cells 
have abundant granular ,foamy cytoplasm.
 
Signet ring carcinoma:  
 Malignant cells show intracytoplasmic mucin accumulation, 
resulting in signet ring appearance. 
 
MIXED TYPES: 
 The mixed ductal and lobular comprises of tumors in which the 
ductal component constitutes between 10 and 90 percent of the 
tumor.  
 
The mixed ductal and special type include any tumors 
composed of mixture of tubule-lobular, tubular,cribriform or mucinous 
carcinoma with ductal NOS in which the later forms over 10 percent of 
the tumor. 
 
UNDETERMINED CARCINOMA: 
 It accounts 3-4% of invasive breast carcinoma. 
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MICROINVASIVE CARCINOMA: 
 Microinvasive carcinoma is defined as any carcinoma in situ of 
the breast showing one or more areas of stromal  invasion not 
surpassing 1mm in thickness. 
 
SPREAD RELATED BREAT CANCER: 
 
1. INFLAMMATORY BREAST CARCINOMA: 
  The  inflammatory  breast carcinoma refers to the whole breast is 
red and warm, with extensive edema of the skin
2,4
, thus resembling the 
look of mastitis.  Clinically presenting inflammatory breast carcinoma 
may be microscopically free from invasion into the dermis and visc 
versa. 
 
2 .PAGET DISEASE: 
 Paget disease is seen  in almost in underlying breast carcinoma of 
in situ ductal type, with or without  invasion of stroma.Clinically it is 
eczema like lesion. 
 
 Histopathologically tumor cells are large clear cells with atypical 
nuclei  usually concentrated beside the basal layer of the epidermis but 
also penetrating the malpighian layer. 
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PROGNOSTIC FACTORS OF INVASIVE DUCTAL 
CARCINOMA OF BREAST: 
 Breast carcinoma is a heterogeneous disease clinically, 
pathologically, radiologically and differs in its biological potential.  
 
 1)  AGE :  Women <50years-best prognosis 
  >50years –bad prognosis 
  <35years– bad prognosis61, higher risk of recurrence and 
distant metastasis. 
 
2) TUMOR SIZE: 
 The size determinator has a greater prognostic significance when 
measured microscopically than grossly. Tumor size and lymph node 
status are two independent prognostic variables
76,77
. 
 
 Saigo and Rosen studied 111 patients with invasive breast 
carcinoma of 1 cm or less in diameter associated with negative nodes 
who were treated with a minimum of a modified radical mastectomy and 
followed for at least 10 years: 75% were alive with no evidence of 
disease, 4% were alive with recurrent carcinoma, 6% had died of 
disease, and 15% had died of other causes. 
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3) STATUS OF LYMPH NODE: 
Axillary lymph node status is an important indicator of systemic 
adjuvant therapy.lt is based on the histological examination of excised 
nodes rather than clinical examination. Nodal metastasis are divided into 
three categories based on size .Numerous studies have shown that 
patients with positive loco-regional nodes have poor prognosis when 
compared to those without nodal involvement
78,79
 . 
 
Lymph node metastasis and prognosis also depends on the number 
and level of regional nodes involved..The prognosis is worst in 
more number of nodes involved. 
 
4) TUMOR SITE:   
 No relationship, but recent  study medial location of the tumor 
was associated 50% risk of systemic relapse and tumor death than 
lateral location. 
 
5) TUMOR CONFIGURATION: 
Tumors with well defined margins have a better prognosis than 
tumors with infiltrative margins. Infiltrative tumors tend to be larger 
and  have associated with axillary lymph node metastasis. Tumors 
with stellate configuration with focal necrosis are associated with worst 
prognosis
80,81
. 
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6) HISTOLOGIC TYPE: 
 Histologic type with excellent prognosis -Tubular, cribriform, 
mucinous and tubulolobular carcinoma.  
 
 Histologic type with good prognosis:  Mixed- ductal NOS and 
special type and classic lobular carcinoma. 
 
 Histologic type with average prognosis: Mixed lobular, medullary 
and atypical medullary carcinoma. 
 
 Histologic type with poor prognosis: ductal NOS,mixed ductal 
and lobular, solid lobular carcinoma and grade 3 basal type carcinoma. 
 
7) LYMPHOVASCULAR INVASION: 
 
1. Tumor emboli in clear spaces with endothelial lining. 
 
2. Tumor emboli do not assume the same shape as the lymphovascular 
vessel. 
 
 Lymphovascular invasion is specifically of prognostic value in 
node negative disease and predicts local recurrence after breast 
conservation surgery and flap recurrence following mastectomy
82
. 
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8) MICROSCOPIC GRADE:  
 
 The important part of oncologic pathology has been the 
identification  that the morphological appearance of  tumors can be  
correlated with the grade of malignancy.
83 
 
In 1957 Bloom and Richardson developed the grading system 
in the form of numerical scoring system.In 1968 Patey and Scarff 
method along with Bloom Richardson method has become modified 
Bloom Richardson grading Method
83
. In 1982 Elston modified the 
Scarff Bloom Richardson method to improve the assessment of mitotic 
figures. 
 
In 1991 Nottingham improved the objectivity of histological 
grading  for assessment of each component factor.Leslie et states that 
histologic grading of invasive breast carcinoma is a valiable prognostic 
feature. The histologic grading system is a simple and cost effective 
method which serves to evaluate morphological characteristics 
semiquantitatively. 
 
 Jean. F. Simpson et al states that the Nittinghamm Combined 
Histologic Grade (NCHG) system is a modification  of Scarff-Bloom-
Richardson grading system, which combines the analysis of glandular 
differentiation, nuclear grade, and mitotic activity.
84 
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Histologic grading system should be done in formalin fixed 
paraffin embedded tissue sections.The assessment of mitotic figures  
affected by delayed formalin fixation.The thickness of section is 4 to 5 
microns and staining method is H&E staining method.
83 
 
Pure tubular, Mucinous and cribriform carcinomas were graded 
as grade1. Medullary carcinoma was placed under grade 3. Invasive 
lobular carcinomas were also graded using this method. Pleomorphic 
variant of lobular carcinoma were graded as grade 3. For mixed 
carcinoma, grading proved to be a better prognostic factor than typing 
alone
 85
. 
 
The most widely accepted Nottingham modification of Scarff 
Bloom Richardson grading system was used. They include 
• Tubule formation 
• Nuclear pleomorphism 
• Mitotic count 
 
9) TUBULE FORMATION: 
Tubular structures are those with central lumen surrounded by 
polarized tumor cells. Solid clusters with reversal of polarity seen in 
micropapillary carcinoma should be scored 3 for tubule formation. All 
58 
areas of the tumor should be scanned and the proportion of the tumor 
occupied by definitive tubular structures with central luminal space 
is assessed. 
 
   1 point :      Tubular formations in >75% of the tumor 
   2 point :       Tubular formations in 10-75% of the tumor 
   3 point :  Tubular formations in <10% of the tumor 
 
10) NUCLEAR PLEOMORPHISM:  
 Assessment of nuclear pleomorphism is the subjective element of 
histological grade.Fritz Rank et al states that criteria for nuclear 
pleomorphism includes irregularity in size, shape and staining of 
nuclei
86
.The tumor areas having cells with greatest atypia should be 
evaluated. 
 
1 Point: Nuclei with minimal variation in size and shape. 
2 Point: Nuclei with moderate variation in size and shape. 
3 Point: Nuclei with marked variation in size and shape. 
 
11) TUMOR MITOTIC COUNT: 
 It is most prognostically  significant of the  grading system. 
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Morphologic criteria for mitotic figures: 
1) Absent nuclear membrane 
2) Clear hairy extention of the nuclear material, either clotted in a plane 
( metaphase/ anaphase) or in separate clots.(Telephase). 
3) The surrounding cytoplasm should not be eosinophilic. 
 
 Two parallel clearly separate chromosome clots should be 
counted as separate mitosis. Spiky or triangular nucleus with 
eosinophilic cytoplasm favours apoptosis. Mitotic score depends on the 
number of mitosis per high power field. The size of the high power field 
should be standardized. 
 
 According to Bloom- Richardson grading system  the mitotic 
figures are to be counted only at the periphery of the tumor.  
 
 The mitotic counting begin in the most mitotically active area. 
Atleast 10 high power field be counted in the same area. 
 
 Kupio and collan established substantial variation  of Bloom 
Richardson grading system depending on the mitotic rate and field 
size
87
. A minimum of 10 field at the periphery of  tumor to counted. The 
mitotic figure should be counted when one notices atleast one                     
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mitotic figure and then proceed to ten consecutive  non overlapping 
fields. 
3 to 5 points- Well differentiated tumor (Grade I) 
6 to 7 points-  Moderately differentiated tumor (Grade II) 
8 to 9 point-   Poorly differentiated tumor (Grade III) 
 
 
OTHER PROGNOSTIC FACTORS:  
NECROSIS: 
 Extensive  tumor necrosis is associated with high incidence of 
lymph node metastasis and survival rates also decreased. 
 
TYPE OF MARGINS: 
 Tumors with pushing margins are associated with good prognosis 
than with infiltrative margins. 
 
MICROVESSEL DENSITY: 
 Invasive carcinoma having a prominent vascular component in the 
surrounding stroma are more aggressive .High grade tumors are associated 
with high score of  MVD. 
 
ELASTOSIS: 
  The pathogenesis and significance of elastosis in breast 
carcinoma to be quite obscure.It is increased in invasive carcinoma  but 
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more prominent in lobular carcinoma.Tumors lacking elastosis have 
showed  lower rate of response to endocrine therapy
115
. 
 
STROMAL REACTION: 
 Tumors with a lack of inflammatory reaction at the periphery 
have a lesser degree of nodal metastases and presumably a better 
prognosis. 
 
FIBROTIC FOCI:  
 Presence of scar like area  in centre of tumor  is an unfavourable 
prognosis
2
. 
 
SKIN AND NIPPLE INVASION:  
 Presence of skin invasion correlates with decreased survival 
rate.The  tumor invasion of nipple is related with high incidence of 
axillary metastasis 
2
. 
 
LYMPHATIC  VESSEL AND PERINEURAL INVASION: 
 This is associated with increased  risk of recurrence. 
 
ER/PR RECEPTORS: 
  The recent use of  immunohistochemistry  is to identify 
nuclear hormone receptors, a result that is correlated with a 
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superior outcome and is an chief interpreter of response to 
hormonal therapy. ER-positive breast carcinomas show better 
response to hormonal and chemotherapy.
2,4,12 
 
HER2/neu RECEPTOR: 
 The lower survival rate is related with over expression of 
Her2/neu receptors
2
. 
 
RESPONSE TO NEOADJUVANT THARAPY: 
  The majority of patients complete their surgery and 
consequently receive systemic treatment. Neoadjuvant therapy is 
an another method where the patient is treated prior to 
surgery.The fact that the tumor responds to chemotherapy is a 
strong favourable prognostic factor
6
. 
 
ANGIOGENESIS: 
 Tumor angiogenesis refer to the  growth of new blood vessel  
toward and within the tumor.It plays  a central role in both local tumor 
growth and distant  metastasis in breast carcinoma.In normal life, 
angiogenesis has a vital role in reproduction, embrogenesis, 
menstruation and healing and repair. It was first described by Folkman 
et al
72
 in 1971. 
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 Tumor angiogenesis as well as role of measuring  intra tumoral 
microvessel density  are independent prognostic factor in both fibro 
cystic diseases and breast cancer
71
.The college of American pathologist 
has stated thst  the study of quantification of tumor angiogenesis is 
prognostic value in breast carcinoma. 
 
      Tumor angiogenesis is known to be regulated by growth factors 
secreted by host and tumor cells.Solid tumors require 
neovascularization to grow beyond about 1mm
3
. 
 
 Normally the extra cellular matrix and basement membrane is 
degraded by matrix metalloproteinase.There are inhibitors of 
metalloproteinase which are present in tissue.The balance between 
metalloproteinase and their inhibitors are regulated normally. 
 
 With increasing histologic grade and transformation from benign 
to malignant condition,the expression of matrix metalloproteinase is 
increased.There is increased level of matrix metalloproteinase in 
association with angiogenesis
98
. 
 
 For initiation of new vessel formation ,lack of oxygen is an 
important factor.there are two hypoxia inducible substances, which              
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are HIF-I,  and HIF2.Each consists of two subunits ,one is alpha and 
other is beta subunits. 
 
 In premalignant and malignant conditions of breast HIF-1alpha 
level of expression is high.Tumors with well differentiation the level of 
HIF-1 alpha is low
98
. 
 
 Tumor angiogenesis is believed to be co-ordinated  by a fine 
balance between  angiogenic activators and inhibitors .Multiple 
angiogenic factors  have been implicated as positive regulators of 
angiogenesis,such as VEGF and bFGF. 
 
MICROVESSEL DENSITY: 
 Microvessel density (MVD) has become the morphological gold 
–standard for  assessing  the neovacularization  in tumors99. Several 
studies have  demonstrated  that the MVD  is  closely correlated  with 
the  prognosis of breast cancer. It has been demonstrated that increasing 
density of newly formed micro vessels in growing tumors correlated 
closely with increasing number of tumor cells shed into the blood 
stream.  
 
 In recent years, mounting evidence has suggested that 
quantification of  microvessel density (MVD) by immunostaining for 
65 
endothelial cell markers, such as CD34,CD31,von Willebrand factor 
(vWF) may be a useful prognostic predictor in cancer patients. CD34 is 
a transmembrane glycoprotein expressed by haematopoietic stem cells, 
endothelial cells and mesenchymal cells in different tissues including 
breast.  
 
  Fibrocystic  breast disease with the highest vascular density are 
associated with a greater risk of breast carcinoma
101
. High microvessel 
density has been  associated with a poor grade of histologic 
differentiation in invasive duct carcinomas and high risk of axillary 
nodal metastasis
72
 and low survival rate. 
 
MEASUREMENT OF   MICROVESSEL DENSITY : 
  As early in 1972, Brem et al. proposed a microscopic 
angiogenesis grading system to assess the angiogenic status of the 
tumor vasculature .In 1991, Weidner et al
71
 described  a new method to 
assess  microvascular density.  
 
 The evaluation of staining with CD34 (microvessel density; 
MVD) was performed by capillary counting in the 3 most highly 
vascularized areas initially selected ( hot spots) under 40x field. Then a 
400x field was used to count microvessels in each of these areas.  
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Single or clusters of endothelial cells, with or without lumen, 
were considered to be individual vessels. Large vessel with muscular 
wall, microvessel in necrotic area and periphery of the tumor field were 
excluded. 
 
 In a study made by H P Dhakal et a and Fox B et al the Chalkley 
method appears to be the improved method in estimating the prognostic 
impact of vascularity in invasive carcinoma of breast.  
 
Microscopic analysis for areas of micro vessel reflects intra 
tumoral vascularization and hence its malignant potential. 
 
 A study by Weidner et al
71
 shows that angiogenesis of breast 
carcinoma has prognostic significance.  
 
In these studies, angiogenesis was compared to a number of 
clinicopathological  parameters such as patient age, tumour size, 
histological grade,  lymph node status, estrogen receptor status and 
prognosis. 
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MEASURE MENT OF MICROVESSEL DENSITY: 
    Three different  methods  used to assess MVD 
METHOD 1 : 
1. Visual scanning of stained slides at all the magnification  
 (100x,400x) 
2. Semiquantitative grading for CD34 staining. 
3. Review of the slides by 2 experienced pathologists to determine 
the accuracy of this method 
4. To ensure vessel specific staining prior histological has to be  
 done. 
METHOD 2: 
1. Scanning of slide at 100x magnification 
2.  Select three areas with lot of blood vessels( Hot spot) 
3. Absolute number of blood vessels is determined at 400x . 
4.  Average of 3 separate visual counts ,lack of larger vessel and  
     sinusoid was taken as microvessel density. 
 
METHOD 3: 
 In this method, microvessel density was estimated  by using 
computerized image analysis. The three hot spots used for the visual 
count is quantified by computer-based  image analysis. The PC 
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compatible image analysis software can be used for analysis of digitally 
captured images .By using computerized pixel counting , microvessel 
surface area is calculated and expressed as the percentage of hot spot 
occupied by CD 34 immuno staining. 
 
According to Indian journal of pathology and microbiology, 
Maha Mohammed Amin,Zeinab et al
87
 the scoring of microvessel 
density is done as follows 
 
MICRO VESSEL DENSITY SCORING:(MVD GRADE) 
    Mild MVD      -   4-10 capillary 
   Moderate MVD- 11-20 capillary 
    Severe MVD    - 21-28 capillary 
ELASTOSIS: 
           The presence of elastosis or elastic tissue in the stroma of 
sections from breast carcinoma was first described by Cheatle and 
Cutler.  
 
          Elastosis is the presence of focal deposits of elastic tissue in 
abnormal amounts .The significance and pathogenesis of elastosis in 
breast carcinoma is unknown
88
. It is common in infiltrating ductal and 
lobular carcinomas of the breast. Elastic tissue is probably produced by 
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fibroblasts, smooth muscle cells or myofibroblasts, under the simulation 
of the infiltrating cancer cells. 
 
 Elastosis  was located  around carcinomatous tissue mammary 
neoplastic ducts ,around veins and as scaterred foci in the stroma. 
Yellow streaks and flecks may be apparent grossly and probably reflect 
the increased elastic tissue. In H&E stained sections, elastosis is seen as 
a homogenous material with a faintly visible fibrillar appearance
88
. 
 
  In sections stained with the Verhoeff-van gieson method, 
showed densely packed black colored elastin fibrils. Periductal  and 
stromal elastosis are usually observed in invasive carcinoma of breast.
88
 
 
 Epithelial hyperplasia is a premalignant component of fibrocystic  
breast disease and  shows higher degree of elastosis
96
 compared to other 
morphologic changes of fibrocystic disease.The prognostic  significance 
and pathogenesis of elastosis in breast carcinoma is unknown. It is 
common in infiltrating ductal and lobular carcinomas of the breast. But 
in recent study breast carcinomas with no associated elastosis have a 
lower rate of response to endocrine therapy than those with gross 
elastosis.
97 
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 In a  study by Curt LundMark et al 
88
 the  presence of  Elastosis 
was higher in non-irradiated patients as well asthese who belonged to 
the age group of 60-69 years. The preoperative management could be 
probably be a reason for reduction in tissue  resulting in  condensation 
of areas with elastosis. 
 
 Jackson and Orr  et al
100
 states,that the condensed elastic tissue 
could be seen grossly as flecks and streaks of yellow material in all 
scirrhous breast cancer.In many breast cancer ,the elastosis  is relatively 
difficult to classify histologically  with logical accuracy whether the 
elastosis  was a periductal elastin hyperplasia or a new development of 
elastin fibrils not related with the ductal walls. 
 
ELASTOSIS GRADE: 
According to the study by Curt Lundmark
88
  grade of elastosis followed 
           Grade 0 -  No elastosis 
           Grade 1-  Mild to moderate degree of elastosis 
          Grade 3-  Gross elastosis 
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MATERIALS AND METHODS 
 
STUDY DESIGN : 
 Descriptive study 
PLACE OF STUDY : 
 Department of pathology ,Coimbatore medical college hospital 
Coimbatore. 
STUDY PERIOD : 
 April 2013 –July 2014 
INCLUSION CRITERIA : 
 All  breast specimens  including mastectomy and breast biopsy 
specimen received in the deparment  of pathology,Coimbatore medical 
college hospital. 
EXCLUSION CRITERIA: 
1) Patient on chemotherapy and radiotherapy 
2) Male breast specimens 
3) Ill fixed specimens 
 
All mastectomy specimens will be received in 10% formalin. These 
were grossed and macroscopic features noted. The tissue was then 
processed routinely paraffin sections  were cut at 4 to 5 μm                  
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thickness and stained by H& E ,Verhoeff van Gieson stain and then 
immunohistochemical study for CD34 was done. 
 
HEMATOXYLIN AND EOSIN  STAINING PROCEDURE 
REAGENTS : 
1)  Erhlich,s Hematoxylin solution 
2)  Eosin Y solution 1% 
3)  Acid alcohol  solution 1% 
TECHNIQUE : 
1.  Deparaffinise the sections 
2.   The sections are immersed in xylene for thirty seconds 
3. Place in isoprophyl alcohol for fifteen minutes 
4.  Tap water wash for 5 minutes 
5. Sections are stained with Erhlich,s Hematoxylin for ten to fifteen  
minutes  and washed in top water 
6. Differentiate in 1% acid alcohol solution – 2 to 3 dips 
7. Then blueing for ten minutes 
8. Counterstain wih 1% Eosin solution -2 to 3 dips 
9.  Tap water wash for 5 minutes 
10. Sections are  air dried 
11. Finally dipped in xylene  
12. DPX mounting 
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VERHOEFF-VAN GIESON STAINING TECHNIQUE: 
REAGENTS: 
SOLUTION-A 
1) Haemotoxylin-          5 gm 
2) Absolute alcohol-       100ml 
SOLUTION-B 
1) Ferric chloride-          10gm 
2) Distilled water-           100ml 
SOLUTION-C- ( LUGOLS IODINE SOLUTION) 
1) Iodine   -       1gm 
2) Potassium iodide -   2gm 
3) Distilled  water -     100ml 
WORKING SOLUTION-D 
     Solution (A)  -      2oml 
     Solution (B)  -       8ml 
     Solution (C)  -     8ml 
Add in the above order and between addition mix. 
PROCEDURE: 
1) Dewax sections and bring to water 
2)  Cover with staining  solution for 30 minutes 
3)  Rinse in water 
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4) Differentiate in 2% aqueus ferric chloride  until elastic fibres 
apper  black on grey background. 
5)  Rinse in water 
6)  Dip in 95% alcohol to remove any staining due to iodine alone 
7)  Counterstain with Van Gieson solution for 1-2 minutes 
8) Blot dry to remove excess stain (don‟t wash) 
9) Dehydrate clean and mount. 
RESULTS: 
           Elastic tissue fibers – black  
           Other tissue elements - yellow 
METHODS OF IMMUNOHISTOCHEMISTRY: 
This method  involves in two step indirect technique. 
1) The primary antibody binds with specific epitopes. 
2) This is followed by detection of antigen –antibody reaction –
called caloriemetric reaction. 
REAGENTS USED: 
1. Peroxide block :3% hydrogen peroxide in water 
2. Power block reagent 
3. Chromogen:DAB substrate-3,3-diaminobenzidine 
4. Liquid DAB substrate 
5. Reagent of super enhancer 
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6. Poly-HPR Reagent 
7. Mayers hematoxylin – counter stain 
8. Buffer solutions 
BUFFERS USED IN IHC 
1.TRIS EDTA: pH-9.0 
         TRIS buffer salt:       6.05 gm 
         Disodium EDTA:       0.744 gm 
         Distilled  water:           1000 ml 
2. TRIS BUFFER:Ph-6 
        TRIS buffer salt :        0.605 gm 
        Sodium chloride:         8 gm  
        Distilled water:            1000 ml  
        1N hydrochloric acid-    3ml 
3. CITRATE BUFFER: pH-6 
         Trisodium citrate :     2.94 gm 
         Distilled water:           1000 ml 
        1N hydrochloric acid:   5 ml 
IHC PROCEDURE METHOD: 
1)  First tissue sections are  deparaffinised in xylene for 30 minutes 
2)  Then absolute  alcohol wash for five minutes  with two changes 
3)  Follows tap water wash for  ten minutes 
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4)  Rinse in distilled water for  five minutes 
5)  Then retrieval of antigen is done by placing the slides is placed in  
      microwave  with appropriate  buffer solutions 
6)   Cool in room temperature  then  rinse  in distilled water 
7) Wash in buffer of TBS for 5minutes  with two changes 
8)  Treat with  peroxide block  for  ten minutes 
9)  Wash in buffer of TBS for five minutes with two changes 
10)  Treat with  peroxide block for ten minutes 
11)  Then drain the slides  treat  with primary antibody 
12)  Wash in buffer of TBS for five minutes with two changes 
13)  Then cover the slides  with superenhancer for thirty minutes 
14) Wash in buffer of TBS for five minutes with two changes 
15)  Then apply reagent of poly HRP and leave for thirty minutes 
16)  Wash in buffer of  TBS for five minutes with two changes 
17)  Then  treat  with DAB chromogen with  substrate buffer  for five  
       to  eight  minutes. 
18) Wash in buffer of TBS for five minutes with two changes 
19)  Tap water wash for five minutes 
20)  Couterstain with mayers hematoxylin for one minute 
21)  Then tap water wash for five minutes 
22 )  Air dry and mount in DPX   
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OBSERVATIONS AND RESULTS 
 
ANALYSIS OF FIBROCYSTIC BREAST DISEASE CASES 
 
Total of 30 cases were studied and the following observations 
were  obtained. 
Table  :  1 
Distribution of Fibrocystic breast disease cases according to 
different age groups 
AGE(Years) NUMBER PERCENTAGE (%) 
20-39 15 50% 
40-49 12 40% 
50-59 3 10% 
≥60 0 0% 
 
Majority of Fibrocystic breast disease cases belonged to 20-39 
years of age group (50%) 
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Chart  :  1 
Distribution of Fibrocystic breast disease cases according to 
different age groups 
. 
 
The peak age group of fibrocystic breast disease is 20-39 years. 
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Table : 2  
 Distribution of  morphological changes in Fibrocystic breast 
disease 
          
MORPHOLOGICAL CHANGES NUMBER 
Cyst formation 14 
Fibrosis 10 
Apocrine metaplasia 5 
Ductal epithelial hyperplasia 20 
Adenosis 1 
Calcification Not seen 
Chronic inflammation Not seen 
Fibroadenomatoid change Not seen 
 
 The most common morphological changes were cyst formation, 
epithelial hyperplasia and fibrosis. 
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Chart   : 2  
Distribution of morphological changes in Fibrocystic breast disease 
 
 
 The most common morphological change were ductal epithelial 
hyperplasia,cyst formation and fibrosis. 
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Table :  3 
Correlation of epithelial  hyperplasia and grade of elastosis 
 
 
Chi-square total=0.230 (p value>0.05)              
 
In this study Elastosis is more commonly associated with 
epithelial hyperplasia. 
 
  
 
 
MORPHOLOGY 
ELASTOSIS GRADE 
GRADE 
0 
GRADE 
1 
GRADE 
2 
Total 
Epithelial hyperplasia 
Absent 
7(23.4%) 3(10%) 0(0%) 10(33.4%) 
Epithelial hyperplasia 
Present 
5(16.6%) 9(30%) 6(20%) 20(66.6%) 
Total 12(40%) 12(40%) 6(20%) 30(100%) 
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Chart  :  3 
Correlation  of  epithelial hyperplasia and grade of elastosis  
 
 
ELASTOSIS GRADE 
 
              In this study the correlation between epithelial hyperplasia and 
grade of elastosis was statistically not significant ( pvalue>0.05) 
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Table :  4 
Correlation of epithelial hyperplasia with micro vessel density score 
(grade) 
Chi-square total=0.001 (p<0.05) 
 
In this study that severe grade of Microvessel density associated 
with epithelial hyperplasia.This is statistically significant. 
 
 
 
 
 
 
MORPHOLOGY MVD SCORE (Grade) 
MILD MODERATE SEVERE Total 
Epithelial hyperplasia 
Absent 
4( 13.3%) 4(13.3%) 2(6.6%) 10(33.3%) 
Epithelial hyperplasia 
Present 
5(16.6%) 6(20%) 9(30%) 20(66.7%) 
Total 9(30%) 10(33.4%) 11(36.6%) 30(100%) 
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Chart :  4  
 Correlation of epithelial hyperplasia with micro vessel  
density score (grade) 
 
 
MICROVESSEL DENSITY SCORE(GRADE) 
 
 
A= EPITHELIAL HYPERPLASIA ABSENT 
B= EPIYHELIAL HYPERPLASIA PRESENT 
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ANALYSIS OF INVASIVE DUCTAL CARCINOMA- 
NOS TYPE CASES 
 
Total of  30 cases were studied and following results obtained 
Table:  5  
 Distribution of Invasive ductal carcinoma-Nos type cases according 
to different age groups 
 
 
In  the table majority of Invasive ducctal carcinoma-Nos type 
cases belonged to  50-59 years of age groups (40%) 
 
 
AGE (Years) NUMBER PERCENTAGE (%) 
20-39 2 6.6% 
40-49 7 23.4% 
50-59 12 40% 
≥60 9 30% 
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Chart :  5 
Distribution of invasive ductal carcinoma-nos type cases according 
to different age groups 
(IDC-NOS) 
 
 
The peak age group of Invasive ductal carcinoma –Nos type cases 
-50-59 years. 
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Table : 6   
Correlation of Micro vessel density grade with the age of the 
Invasive duct carcinoma-Nos type cases 
 
No significant correlation between Microvessel density grade and 
age of Invasive ductal carcinoma cases was noted. 
 
 
 
AGE (Years) MVD SCORE (GRADE) 
MILD MODERATE SEVERE Total 
20-39 1(3.3%) 1(3.3%) 0(0%) 2(6.6%) 
40-49 4(13.4%) 2(6.6%) 1(3.3%) 7(23.4%) 
50-59 8(26.6%) 3(10%) 1(3.3%) 12(40%) 
≥60 4(13.4%) 3(10%) 2(6.6%) 9(30%) 
TOTAL 17(56.6%) 10(33.4%) 3(10%) 30(100%) 
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                                          Chart  :  6 
Correlation of Micro vessel density grade with the age of the 
Invasive duct carcinoma-Nos type cases 
 
This table shoes that the grade of microvessel density does not 
correlate with age of occurrence of invasive ductal carcinoma-nos type. 
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Table : 7 
Distribution of Invasive ductal carcinoma-Nos type cases according 
to histological grade 
 
HISTOLOGICAL 
GRADE 
NUMBER PERCENTAGE (%) 
GRADE I 6 20% 
GRADE II 14 46.6% 
GRADE III 10 33.4% 
 
Majority of Invasive ductal carcinoma cases were histological gradeII. 
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Chart : 7 
Distribution of Invasive ductal carcinoma-Nos type cases according 
to histological grade 
HISTOLOGIC GRADE 
 
Majority of tumors were histologically grade II(46.6) 
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Table  :  8 
 Distribution of Invasive ductal carcinoma-nos type cases with 
regard to  elastosis grade 
 
 
There was no significant association elastosis and age of Invasive 
ductal carcinoma-Nos  type cases. 
  
 
 
 
AGE(Years) ELASTOSIS (grade) 
0 1 2 Total 
20-39 2(6.6%) 0(0%) 0(0%) 2(6.6%) 
40-49 4(13.4%) 2(6.6%) 1(3.4%) 7(23.4%) 
50-59 7(23.4%) 3(10%) 2(6.6%) 12(40%) 
≥60 5(16.8%) 2(6.6%) 2(6.6%) 9(30%) 
Total 18(60%) 7(23.4%) 5(16.6) 30(100%) 
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Chart :  8 
Distribution of  Invasive ductal carcinoma-nos type cases with 
regard to elastosis grade 
 
 
G 0-   GRADE 0 ELASTOSIS 
G 1-    GRADE 1ELASTOSIS 
G 2 -    GRADE 2 ELASTOSIS 
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Table :  9 
Correlation of histological grade with microvessel density grade 
Chi-square test=0.002 (p<0.05) 
 
Severe grade Microvessel density was seen in  with grade III 
tumors and grade II tumors. 
 
 
 
 
 
 
HISTOLOGICAL 
GRADE 
MVD GRADE (SCORE) 
Mild Moderate Severe Total 
GRADE I 1(3.4%) 3(10%) 2(6.6%) 6(4%) 
GRADE II 2(6.6%) 5(16.6%) 7(23.4%) 14(56%) 
GRADE III 1(3.4%) 2(6.6%) 7(23.4%) 10(40%) 
Total 6(20%) 10(33.4%) 14(46.6%) 30(100%) 
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Chart :  9 
 Correlation of histological grade with microvessel density grade 
 
MVD  GRADE 
 
The correlation between histological grade with Microvessel 
density grade is statistically significant. 
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Table  :  10 
Correlation of histological grade with elastosis grade 
 
 Chi-square test=0.118(p>0.005) 
 
Significant correlation between elastosis and histological grade 
tumor was not seen. 
 
 
 
ELASTOSIS 
GRADE 
HISTOLOGICAL GRADE 
I II III Total 
0 3(10%) 10(33.4%) 5(16.6%) 18(60%) 
1 2(6.6%) 2(6.6%) 3(10%) 7(23.4%) 
2 1(3.4%) 2(6.6%) 2(6.6%) 5(16.6%) 
Total 6(20%) 14(46.6%) 10(33.4%) 30(100%) 
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Chart 10 : 
 Correlation of histological grade with elastosis grade 
 
HG – HISTOLOGICAL GRADE 
GRADE 0/1/2 – ELASTOSIS GRADE 
 
 
 
 
 
 
FIG 1 :  FCD with Ductal Epithelial Hyperplasia and Cyst formation 
(H&E Section) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 2 :  FCD with Apocrine  Metaplasia 
( H&E Section) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 3 :  Invasive Ductal Carcinoma  Nos Type    
(H&E Section)-10 x View 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 4 :  Invasive Ductal Carcinoma  Nos Type     
(H&E Section) – 40 x view  
  
 
 
 
 
 
 
 
 
FIG 5:  FCD  With  Periductal Elastosis (VVG Special Stain) 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 6 :  IDC-NOS with Peridctal and Stromal Elastosis  
(VVG special stain) 
  
 FIG 7:  FCD – Micro vessel density CD 34 immuno stain – Mild degree (40X) 
 
 
 
 
 
 
 
 
 
 
 
FIG 8 : FCD – Micro vessel density CD 34 immuno stain –  
Severe degree (40X) 
  
   
 
 
 
 
 
 
 
 
 
FIG 9:  IDC-NOS Micro vessel density CD 34 immuno stain –  
Mild degree (10X) 
 
 
 
 
 
 
 
 
 
 
 
FIG 10:  IDC-NOS  Micro vessel density CD 34 immuno stain –  
moderate degree (10X) 
 FIG 11 :  IDC-NOS  Micro vessel density CD 34 immuno stain –  
Severe degree (10X) 
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DISCUSSION 
 
 Fibrocystic breast disease is a benign condition of the breast due 
to exaggerated hormonally mediated response.The peak age of 
occurrence is  between 30-50years.  
 
 In this present study  majority of Fibrocystic breast disease cases 
belonged to age of 20-39 years (50%).This correlated with a study done 
by Shaaban AM, Sloane JP
102
 et al. 
 
 In the present study the most common morphological changes  of 
Fibrocystic breast disease were cyst formation and epithelial 
hyperplasia followed by fibrosis, apocrine metaplasia, and adenosis. 
Ductal epithelial hyperplasia poses less than twice the risk for malignant 
transformations.   
 
 In present study grade of elastosis was commonly associated with 
ductal epithelial hyperplasia,but was not stastically significant(p>0.05). 
This was in accordance with study by Parfrey and Doyle et al
91
 showed 
as periductal and interstitial elastosis in the Fibrocystic breast disease 
increased gradually with the severity of the epithelial hyperplasia. 
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 In present study  the grade of microvessel density correlates  
significantly with epithelial hyperplasia (p value< 0.05).A study by 
Guinebretiere J.M. et al  and J E Bluff,SR Menakuru et al 
101
showed 
similar results. 
 
 Breast cancer is the leading cause of cancer deaths among 
women. Results from experimental studies suggest that tumor 
progression and metastasis in breast cancer is angiogenesis dependant.  
 
 Angiogenesis has gained importance as a prognostic indicator in 
tumor progression. Tumor angiogenesis is generally measured by 
quantifying micro vessel density in sections immuno stained for 
vascular endothelial cell markers, such as CD34.  
 
 Takao Kato et al
104
 found this marker to be a significant 
independent prognostic factor associated with long term survival in 
Japanese breast cancer patients, especially in node-negative patients. 
 
 In this present study majority of Invasive ductal carcinoma-nos 
type  cases belong to age of 50 to 59 years. 
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  A study conducted by ChungM et al 
105 
and Michel JKerin et al
106
 
showed  similar results. A study by YildirimE,DalgicT et al
107
 showed 
age was an independent prognostic factors in breast cancer. 
 
 In  the present study  predominant tumors were histologically 
grade II  ( 46.60%) followed by  grade III ( 33.40%) and grade I ( 20% ) 
A study by Dalton LW, Page DL, Dupont WD et al
108
 showed majority 
of tumors were histologically grade II followed grade I and grade III 
tumors. 
 
 In this present study  there was no positive correlation  between 
Microvessel density grade and age of Invasive ductal carcinoma cases. 
A study by Goulding et al, Costello et al also shows similar results. 
 
          A study by Curt Lundmark  et al 
88
 showed grade  1 and grade 2 
elastosis belong to age of 60 to 69 years and  but no  positive correlation  
between increasing age and grade of elastosis. 
 
 In this study high grade of Microvessel density was seen among 
grade III tumors followed by grade II and grade I tumors .In the present 
study a significant correlation (p value<0.05) is noted between  
histological grade and grade of Microvessel density. Similar to that 
found by Horak et al,
109  
 Weidner et al
71
and  Bosari et al. 
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 However, Goulding et al, Van Hoef et al
110
 failed to find any 
association between Micro vessel density and prognosis.  
 
In this present study grade 2 elastosis was seen among 50-59 
years age group,grade 1 elastosis among >60 years and grade 0 elastosis 
among age of 20-39 years.A study by Curt Lundmark et al
88
 showed 
that grade 1 and grade 2 elastosis  was common between 60-69 years of 
age. 
 
In this present study the correlation between histological grading 
and elastosis grade deos not apper to be a prognostic significance.But 
study by Jackson and Orr et al
90
 found that grade II and grade III tumors 
showed  69.9% and 63.1% of elastosis respectively. 
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SUMMARY   
 
 The present study was conducted at Coimbatore medical                
college, Coimbatore during the year of April 2013 to july2014, titled  as     
“AN ASSESSMENT OF ANGIOGENESIS  AND ELASTOSIS IN 
FIBROCYSTIC BREAST DISEASE AND INVASIVE BREAST 
CARCINOMA”. It is a descriptive study  consists of thirty cases of  
fibrocystic breast diseases and thirty cases of invasive ductal carcinoma. 
Immunohistochemical study for CD34 was done for all  the cases to 
grade  the microvessel density. In addition Verhoeff-VanGieson stain 
was done  to grade the elastosis. Patients who had underwent  
preoperative  neo adjuvant chemotherapy  and radiotherapy were 
excluded. Statistical analysis was done and compared with similar 
previous studies. 
 
The present study showed the following results: 
1. Majority of the cases of fibrocystic breast disease were in to the 
age group between 20-39 years. 
 
2. Most common morphological changes of fibrocystic disease were 
cyst formation and usual ductal epithelial hyperplasia. 
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3. The association between ductal epithelial hyperplasia and grade 
of microvessel density was statistically significant.(p<0.05) 
4. The association between ductal epithelial hyperplasia and grade 
of elastosis was not statistically significant.(p-value>0.05) 
5. Most common age of presentation of invasive duct breast 
carcinoma –Nos type were  50-59 years. 
6. Most of the invasive duct breast carcinoma –Nos type were grade 
II tumors (46.6%). 
7. The  correlation between grade of microvessel density and age of 
invasive ductal carcinoma was not statistically significant. 
8. The correlation between grade of elastosis and the age of Invasive 
duct carcinoma-Nos type cases was not statistically 
significant.Which may be , probably due to inadequate sampling. 
9. The correlation between histological grade of invasive ductal 
carcinoma-Nos type and  grade of microvessel density  was 
statistically significant(p<0.05) in contrast to elastosis which was 
statistically insignificant.  
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CONCLUSION 
 
     To conclude the available prognostic factors in breast 
carcinoma have been studied extensively.Angiogenesis in breast 
carcinoma has attracted interest as a prognostic indicator.The study 
of microvessel density using CD34 as one of the novel marker, has a 
promising role in targeted therapy. 
        Tumors lacking elastosis have showed lower rate of 
response to endocrine therapy. So, this might be useful as predictive 
marker of response to endocrine  therapy. 
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ANNEXURE-I 
PROFORMA 
Name:                                                                            Age: 
Ward:                                                                            IP/OP No: 
Address: 
Presenting complaints: 
                Breast lump 
                Pain 
       Nipple discharge 
     Skin ulceration 
Duration of presenting complaint: 
Past history: 
               History of previous surgeries for breast lump 
               History of chemotherapy/Radiotherapy 
               History of breast lump in other breast 
Family history: 
Personal history: 
              Diet 
              Menstrual history 
              Breast feeding history 
General examination 
        Nourishment:                             Built:                              Consious: 
        Pallor:                Jaundice:             Cyanosis:                  Clubbing: 
        PR:                          RR:                BP:                 Febrile/Afebrile:   
        Lymphadenopathy:                                 Edema: 
Local examination of the breast 
       Side: Right/Left 
       Quadrant:Upper/Outer/Inner/Lower/Central 
       Size of the tumor: 
       Fixity to skin: Yes/No                      Fixity to underlying Fascia: 
Yes/No   
Examination of axillary lymph node: 
       Number of node: 
       Mobile/Fixed: 
       Size: 
       Group of nodes : Anterior/Posterior/lateral/apical 
Gross examination of modified radical mastectomy specimen 
       Size of the specimen including skin, nipple & Areola: 
       Size of the tumor: <2cm/2-5cm/>5cm 
       Margins: Infiltrative/circumscribed 
       Quadrant: Outer/Inner/Central 
Histologic diagnosis: 
Any special type: 
Lymph node status no: of positive nodes/no: of total nodes examined  
Histologic grading 
                        Tubule formation: 1/2/3 
                        Nuclear pleomorphism: 1/2/3 
                        Mitotis: 1/2/3 
Histologic grade: I/II/III  
 
 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 44 794/13 FCD NOT APPLICABLE
2 38 989/13 FCD NOT APPLICABLE
3 35 1247/13 FCD NOT APPLICABLE
4 40 1849/13 FCD NOT APPLICABLE
5 21 1908/13 FCD NOT APPLICABLE
6 28 2477/13 FCD NOT APPLICABLE
7 32 2505/13 FCD NOT APPLICABLE
8 25 2591/13 FCD NOT APPLICABLE
9 36 2812/14 FCD NOT APPLICABLE
10 22 2813/14 FCD NOT APPLICABLE
11 28 2905/14 FCD NOT APPLICABLE
12 31 3020/14 FCD NOT APPLICABLE
13 42 3025/14 FCD NOT APPLICABLE
14 34 P51/14 FCD NOT APPLICABLE
15 38 P79/14 FCD NOT APPLICABLE
16 42 P376/14 FCD NOT APPLICABLE
17 38 P553/14 FCD NOT APPLICABLE
18 45 P654/14 FCD NOT APPLICABLE
19 43 P753/14 FCD NOT APPLICABLE
20 26 P890/14 FCD NOT APPLICABLE
21 42 P954/14 FCD NOT APPLICABLE
22 56 P966/14 FCD NOT APPLICABLE
23 41 E394/14 FCD NOT APPLICABLE
24 49 E416/14 FCD NOT APPLICABLE
25 58 E432/14 FCD NOT APPLICABLE
26 36 E502/14 FCD NOT APPLICABLE
27 47 E550/14 FCD NOT APPLICABLE
28 51 E573/14 FCD NOT APPLICABLE
29 43 E632/14 FCD NOT APPLICABLE
MASTER CHART 
SEVERE GRADE
MLID GRADE
MODERATE GRADE
SEVERE GRADE
MLID GRADE
MODERATE GRADE
MILD GRADE
MODERATE GRADE
MILD GRADE
GRADE1
GRADE2
GRADE0
GRADE1
GRADE2
GRADE1
GRADE1
GRADE0
ELASTOSIS GRADEHISTOLOGIC GRADE
HISTOLOGIC 
DIAGNOSIS
HPE NOAGE
GRADE2
MODERATE GRADE
SEVERE GRADE
MILD GRADE
SEVERE GRADE
MODERATE GRADE
S.NO
MICROVESSEL DENSITY 
SCORE(GRADE)
MILD GRADE
SEVERE GRADE
SEVERE GRADE
MODERATE GRADE
MODERATE GRADE
MODERATE GRADE
MILD GRADE
SEVERE GRADE
MILD GRADE
MODERATE GRADE
MILD GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
SEVERE GRADE
GRADE 0
GRADE 0
GRADE 1
GRADE1
GARDE2
GRADE 1
GRADE 0
GRADE1
GRADE 0
GRADE 1
GRADE 2
GRADE0
GRADE 1
GRADE 0
GRADE 1
GRADE 0
GRADE2
GRADE 0
GRADE 1
GRADE 0
ELASTOSIS GRADEHISTOLOGIC GRADE
HISTOLOGIC 
DIAGNOSIS
HPE NOAGES.NO
MICROVESSEL DENSITY 
SCORE(GRADE)
30 46 E745/14 FCD NOT APPLICABLE
31 56 670/13 IDC-NOS I
32 55 767/13 IDC-NOS II
33 52 801/13 IDC-NOS II
34 65 858/13 IDC-NOS III
35 55 1029/13 IDC-NOS II
36 50 700/14 IDC-NOS I
37 40 793/14 IDC-NOS II
38 81 859/14 IDC-NOS II
39 50 860/14 IDC-NOS III
40 40 894/14 IDC-NOS I
41 52 931/14 IDC-NOS III
42 65 966/14 IDC-NOS II
43 45 1642/14 IDC-NOS II
44 38 1832/14 IDC-NOS II
45 66 1877/14 IDC-NOS I
46 52 1895/14 IDC-NOS II
47 49 2039/14 IDC-NOS II
48 65 2179/14 IDC-NOS III
49 58 2050/14 IDC-NOS II
50 53 2135/14 IDC-NOS II
51 45 2179/14 IDC-NOS II
52 38 2240/14 IDC-NOS III
53 45 2296/14 IDC-NOS I
54 52 2461/14 IDC-NOS III
55 49 2462/14 IDC-NOS II
56 55 2516/14 IDC-NOS III
57 73 2622/14 IDC-NOS II
58 65 2676/14 IDC-NOS III
59 72 2762/14 IDC-NOS I
60 61 2773/14 IDC-NOS III
GRADE 0
MILD GRADE
 GRADE 2
GRADE 0
MODERATE GRADE
MODERATE GRADE
GRADE 0
GRADE 2
GRADE 1
GRADE 0
GRADE 2
GRADE 0
GRADE 0
SEVERE GRADE
MILD GRADE
SEVERE GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
SEVERE GRADE
MODERATE GRADE
MODERATE GRADE
MODERATE GRADE
GRADE 0
GRADE 1
SEVERE GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
MILD GRADE
SEVERE GRADE
GRADE 0
GRADE 0
GRADE 2
GRADE 1
GRADE 0
GRADE 0
GRADE 2
GRADE 1
GRADE 0
MODERATE GRADE
MODERATE GRADE
SEVERE GRADE
GRADE 1
GRADE 0
GRADE 0
GRADE 0
GRADE1
GRADE 0
GRADE 0
MILD GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
MODERATE GRADE
SEVERE GRADE
SEVERE GRADE
GRDAE0
GRADE 0
GRADE 1
 ABBREVIATIONS 
 
FCD   - Fibrocystic disease 
IDC-NOS  - Invasive ductal carcinoma-not otherwise  
    specified 
DCIS   - Ductal carcinoma in situ 
UDH   -  Usual ductal hyperplasia 
ADH   -  Atypical ductal hyperplasia 
WHO   - World health organisation 
AJCC   - American joint committee classification 
FNAC  - Fine niddle aspiration cytology 
MVD GRADE -  Microvessel density grade 
HG   -  Histological grade 
EG   -  Elastosis grade 
H&E STAIN - Haematoxyline and eosin stain 
IHC   -  Immunohistochemistry 
VVG STAIN -  Verhoeff VonGieson stain 
H&E SECTION -  Haematoxyline and eosin section 
VEGF  -  Vascular endothelial growth factor 
